MICVO's 36% ORR and 79% 12-Month OS in 2L+ HNSCC Support Phase 3 Initiation by Mid-2027
PYXS has more than doubled off its 52-week low of $1.03.
Summary
Updated Phase 1 data for MICVO in 2L+ R/M HNSCC show 36% cORR, 94% DCR, 6.2-month mPFS, and 79% 12-month OS probability, with Phase 3 initiation planned for mid-2027.
Key Events · Product Development and Regulatory · PYXS
-
MICVO Phase 1 Data Update
In 2L+ R/M HNSCC at 5.4 mg/kg with dose cap, MICVO achieved a 36% confirmed ORR (12/33), 94% DCR, 6.2-month mPFS, and 79% 12-month OS probability.
-
Phase 3 Headliner™ Trial Design
The randomized, open-label, 2-arm study will enroll approximately 500 patients, comparing MICVO to investigator's choice (cetuximab, docetaxel, or methotrexate); co-primary endpoints are ORR and OS, with initiation planned for mid-2027.
-
Regulatory Alignment
The company aligned with FDA and EMA on the Phase 3 design; an End of Phase 2 meeting with FDA for dose selection is anticipated in Q1 2027.
-
Safety Profile
No new safety signals emerged; Grade ≥3 TRAEs occurred in 54.3% of patients, the treatment discontinuation rate was 14.3%, and there were 0 treatment-related deaths; dose capping reduced adverse event frequency and severity.
Analysis · PYXS · Life Sciences
Updated Phase 1 data for MICVO in heavily pretreated 2L+ R/M HNSCC show a 36% confirmed objective response rate, 94% disease control rate, median PFS of 6.2 months, and 79% 12-month overall survival probability. These results compare favorably to historical control arms (6-7% ORR, ~2.3 months mPFS). The company has aligned with FDA and EMA on a pivotal Phase 3 design (Headliner™, N≈500, co-primary endpoints ORR and OS) with initiation planned for mid-2027. No new safety signals were observed, and dose capping reduced adverse event severity in high body weight patients. This is a meaningful de-risking event for the lead asset in a $4B+ US addressable market.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.5M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.